Ulta Beauty Lifts FY22 Outlook

While reporting its results for the second quarter on Thursday, Ulta Beauty, Inc. (ULTA) lifted its outlook for the full year 2022.

Looking forward, the company now expects earnings of $20.70 to $21.20 per share and revenues of $9.65 billion to $9.75 billion.

Previously, the company expected earnings of $19.20 to $20.10 per share and revenues of $9.35 billion to $9.55 billion.

Analysts polled by Thomson Reuters currently expect revenues of $9.53 billion for the year. Analysts' estimates typically exclude one-time items.

ULTA closed Thursday's trading at $419.25, up $7.23 or 1.75%, on the Nasdaq. The stock further gained $11.75 or 2.80% in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT